Afatinib in advanced non-small-cell lung cancer

By Di Maio Massimo   Gridelli Cesare   Grossi Francesco   Novello Silvia   de Marinis Filippo  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 493-504

Future Medicine

Access to resources Recommend Favorite

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer

By Riedel Richard F   Febbo Phillip G  

Future Oncology, Vol. 1, Iss. 4, 2005-08 ,pp. : 461-466

Future Medicine

Access to resources Recommend Favorite

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi   Nakagawa Kazuhiko  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

By Motoshima Kohei   Nakamura Yoichi   Sano Kazumi   Ikegami Yoji   Ikeda Takaya   Mizoguchi Kosuke   Takemoto Shinnosuke   Fukuda Minoru   Nagashima Seiji   Iida Tetsuya   Tsukamoto Kazuhiro   Kohno Shigeru  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1299-1304

Springer Publishing Company

Access to resources Recommend Favorite

Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer

By Marinopoulos Spyridon   Skorda Lamprini   Karatapanis Stylianos   Rasidakis Antonis  

Medical Oncology, Vol. 25, Iss. 4, 2008-12 ,pp. : 415-418

Humana Press, Inc

Access to resources Recommend Favorite